- Home
- OACC vs OABI Comparison
OACC vs OABI Comparison
Compare OACC & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OACC
- OABI
- Stock Information
- Founded
- OACC 2024
- OABI 2012
- Country
- OACC United States
- OABI United States
- Employees
- OACC N/A
- OABI N/A
- Industry
- OACC
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- OACC
- OABI Health Care
- Exchange
- OACC NYSE
- OABI Nasdaq
- Market Cap
- OACC 256.3M
- OABI 250.8M
- IPO Year
- OACC 2024
- OABI N/A
- Fundamental
- Price
- OACC $10.47
- OABI $2.10
- Analyst Decision
- OACC
- OABI Strong Buy
- Analyst Count
- OACC 0
- OABI 3
- Target Price
- OACC N/A
- OABI $7.00
- AVG Volume (30 Days)
- OACC 25.5K
- OABI 636.1K
- Earning Date
- OACC 01-01-0001
- OABI 08-06-2025
- Dividend Yield
- OACC N/A
- OABI N/A
- EPS Growth
- OACC N/A
- OABI N/A
- EPS
- OACC N/A
- OABI N/A
- Revenue
- OACC N/A
- OABI $26,744,000.00
- Revenue This Year
- OACC N/A
- OABI N/A
- Revenue Next Year
- OACC N/A
- OABI $45.02
- P/E Ratio
- OACC $96.64
- OABI N/A
- Revenue Growth
- OACC N/A
- OABI 27.07
- 52 Week Low
- OACC $9.95
- OABI $1.22
- 52 Week High
- OACC $10.85
- OABI $4.96
- Technical
- Relative Strength Index (RSI)
- OACC N/A
- OABI 62.35
- Support Level
- OACC N/A
- OABI $1.90
- Resistance Level
- OACC N/A
- OABI $2.19
- Average True Range (ATR)
- OACC 0.00
- OABI 0.14
- MACD
- OACC 0.00
- OABI 0.00
- Stochastic Oscillator
- OACC 0.00
- OABI 55.48
About OACC OAKTREE ACQUISITION CORP III LIFE S
Oaktree Acquisition Corp III Life Sciences is a blank check company.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.